The next generation of studies of anti-HER2 therapy in early breast cancer need to address both the potential to reduce chemotherapy in some patients and additional approaches in others, as defined by their demonstrated sensitivity to short-duration anti-HER2 therapies. Here, ERBB2 is linked to breast cancer.